Niagen Bioscience (FRA:OCD1) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
68 GF Score
Price €2.60
GF Value €3.77
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Niagen Bioscience  (FRA:OCD1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Niagen Bioscience Cyclically Adjusted PB Ratio Related Terms


Niagen Bioscience Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Niagen Bioscience's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niagen Bioscience Cyclically Adjusted PB Ratio Chart

Niagen Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.19 4.10 3.34 11.50 10.15

Niagen Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.75 16.84 10.72 6.67 4.85

FRA:OCD1 vs CAMP, ALEC, ELDN: Cyclically Adjusted PB Ratio Comparison

For the Packaged Foods subindustry, Niagen Bioscience's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Niagen Bioscience Cyclically Adjusted PB Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Cyclically Adjusted PB Ratio falls into.


FRA:OCD1
68GF Score
Niagen Bioscience Inc FRA:OCD1
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niagen Bioscience Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Niagen Bioscience's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Niagen Bioscience's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.915/333.9520*333.9520
=0.915

Current CPI (Jun. 2026) = 333.9520.

Niagen Bioscience Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.281 241.428 0.389
201612 0.252 241.432 0.349
201703 0.231 243.801 0.316
201706 0.495 244.955 0.675
201709 0.599 246.819 0.810
201712 0.820 246.524 1.111
201803 0.694 249.554 0.929
201806 0.632 251.989 0.838
201809 0.524 252.439 0.693
201812 0.432 251.233 0.574
201903 0.338 254.202 0.444
201906 0.240 256.143 0.313
201909 0.419 256.759 0.545
201912 0.306 256.974 0.398
202003 0.253 258.115 0.327
202006 0.313 257.797 0.405
202009 0.270 260.280 0.346
202012 0.217 260.474 0.278
202103 0.551 264.877 0.695
202106 0.523 271.696 0.643
202109 0.449 274.310 0.547
202112 0.410 278.802 0.491
202203 0.341 287.504 0.396
202206 0.292 296.311 0.329
202209 0.315 296.808 0.354
202212 0.360 296.797 0.405
202303 0.345 301.836 0.382
202306 0.332 305.109 0.363
202309 0.344 307.789 0.373
202312 0.344 306.746 0.375
202403 0.357 312.332 0.382
202406 0.380 314.175 0.404
202409 0.405 315.301 0.429
202412 0.576 315.605 0.609
202503 0.653 319.799 0.682
202506 0.687 322.561 0.711
202509 0.755 324.800 0.776
202512 0.817 324.054 0.842
202603 0.899 330.213 0.909
202606 0.915 333.952 0.915

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.60 is trading 31% below its estimated GF Value™ of €3.77.

Key valuation signals for FRA:OCD1:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €3.77 vs. price of €2.60 (31% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score

Get the complete analysis for FRA:OCD1

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€3.77
GF Value